Streetwise Articles

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential'
Source: Streetwise Reports  (10/10/18)
A LifeSci Capital report presented a handful of key points about the firm. More >

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential
Source: Streetwise Reports  (10/10/18)
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. More >

Daniel Carlson

Texas Heart Takes to the CoreoGraft
Source: Daniel Carlson for Streetwise Reports  (10/10/18)
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. More >

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements
Source: Streetwise Reports  (10/9/18)
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. More >

DURECT Receives Return on Schizophrenia Drug Approval
Source: Streetwise Reports  (10/3/18)
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. More >

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters
Source: Streetwise Reports  (10/3/18)
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. More >

Surgical Robotics Developer Demonstrates Technology at Medical Conference
Source: Streetwise Reports  (10/3/18)
A Ladenburg Thalmann report relayed how this Massachusetts company participated at the Transcatheter Cardiovascular Therapeutics annual meeting through a live transmission—the first ever—of a remote interventional procedure using the CorPath GRX system. More >

Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed
Source: Clive Maund for Streetwise Reports  (10/1/18)
As the worldwide movement to ban antibiotics as a growth promoter in animal feed gains traction, technical analyst Clive Maund has called an "immediate strong buy" on a company that has developed an alternative. More >

Life Sciences Company Hits Sales Milestone with Livestock Product
Source: Streetwise Reports  (9/29/18)
With this development, the Canadian firm entered a new geography and an additional market segment. More >

Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
Source: Streetwise Reports  (9/26/18)
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia. More >

NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program
Source: Streetwise Reports  (9/26/18)
A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer. More >

Biotech's Preliminary Immunotherapy Data 'Positive,' Earns Coverage in Medical Journal
Source: Streetwise Reports  (9/26/18)
An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer. More >

Life Science Company Sells Large Order of Non-Antibiotic Growth Promoter for Livestock
Source: Streetwise Reports  (9/25/18)
This is the second large shipment to the Philippine distributor. More >

Frederick Lacy

This Company Has Better Numbers than Tilray at 1/25th the Price
Source: Fincom Investment Partners for Streetwise Reports  (9/24/18)
Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer. More >

Brett Earl

Medical Use of Nitric Oxide Expands as Costs Come Down
Source: Streetwise Reports  (9/19/18)
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. More >

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'
Source: Streetwise Reports  (9/19/18)
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm. More >

Cancer Vaccine Developer Expands Its Collaboration with Merck
Source: Streetwise Reports  (9/19/18)
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner. More >

U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan
Source: Streetwise Reports  (9/18/18)
Permission has been obtained to distribute time-release capsules. More >

Daniel Carlson

Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment
Source: Daniel Carlson for Streetwise Reports  (9/14/18)
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. More >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm
Source: Streetwise Reports  (9/12/18)
An Echelon Wealth Partners report discussed the deal terms.
More >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial
Source: Streetwise Reports  (9/11/18)
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications.

More >

Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device
Source: Streetwise Reports  (9/5/18)
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company. More >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent
Source: Streetwise Reports  (9/5/18)
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. More >

Drug Company Receives $5 Million Milestone Payment
Source: Streetwise Reports  (8/31/18)
Company entitled to receive quarterly earn-out payments from patent agreement. More >

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment
Source: Streetwise Reports  (8/29/18)
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. More >

Showing Results: 26 to 50 of 969 Prev Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts